686 related articles for article (PubMed ID: 20463178)
1. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
3. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
Buhl R; Dunn LJ; Disdier C; Lassen C; Amos C; Henley M; Kramer B;
Eur Respir J; 2011 Oct; 38(4):797-803. PubMed ID: 21622587
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
[TBL] [Abstract][Full Text] [Related]
5. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
Rennard S; Bantje T; Centanni S; Chanez P; Chuchalin A; D'Urzo A; Kornmann O; Perry S; Jack D; Owen R; Higgins M
Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
Kinoshita M; Lee SH; Hang LW; Ichinose M; Hosoe M; Okino N; Prasad N; Kramer B; Fukuchi Y;
Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
Gotfried MH; Kerwin EM; Lawrence D; Lassen C; Kramer B
COPD; 2012 Dec; 9(6):629-36. PubMed ID: 23020650
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.
Mahler DA; Buhl R; Lawrence D; McBryan D
Pulm Pharmacol Ther; 2013 Jun; 26(3):348-55. PubMed ID: 23434446
[TBL] [Abstract][Full Text] [Related]
9. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
[TBL] [Abstract][Full Text] [Related]
11. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
Kornmann O; Dahl R; Centanni S; Dogra A; Owen R; Lassen C; Kramer B;
Eur Respir J; 2011 Feb; 37(2):273-9. PubMed ID: 20693243
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
[TBL] [Abstract][Full Text] [Related]
13. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.
To Y; Kinoshita M; Lee SH; Hang LW; Ichinose M; Fukuchi Y; Kitawaki T; Okino N; Prasad N; Lawrence D; Kramer B
Respir Med; 2012 Dec; 106(12):1715-21. PubMed ID: 23040786
[TBL] [Abstract][Full Text] [Related]
14. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
Kerwin EM; Williams J
Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
[TBL] [Abstract][Full Text] [Related]
15. Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
Decramer M; Rossi A; Lawrence D; McBryan D
Respir Med; 2012 Dec; 106(12):1706-14. PubMed ID: 23031496
[TBL] [Abstract][Full Text] [Related]
16. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
Jones PW; Mahler DA; Gale R; Owen R; Kramer B
Respir Med; 2011 Jun; 105(6):892-9. PubMed ID: 21397482
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
Cope S; Capkun-Niggli G; Gale R; Lassen C; Owen R; Ouwens MJ; Bergman G; Jansen JP
Value Health; 2012 May; 15(3):524-33. PubMed ID: 22583463
[TBL] [Abstract][Full Text] [Related]
18. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
19. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
20. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
Hoshino M; Ohtawa J; Akitsu K
Pulm Pharmacol Ther; 2015 Feb; 30():128-33. PubMed ID: 25183687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
